AdultPediatricDosage Forms & Strengths injection, lyophilized powder for reconstitution 250mg/vial solution for SC injection 125mg/mL prefilled syringe 125mg/mL autoinjector Rheumatoid Arthritis Indicated for moderately to severely active rheumatoid arthritis (RA) in adults IV infusion <60 kg: 500 mg 60-100 kg: 750 mg >100 kg: 1000 mg Maintenance: Above dose repeated q2Weeks X2, then q4Weeks SC injection SC administration may be initiated with or without an IV loading dose If IV loading dose is used, administer first SC injection within 1 day of infusion 125 mg SC qWeek Transitioning from IV to SC: Administer first SC dose instead of scheduled IV dose Psoriatic Arthritis Indicated for adults with active psoriatic arthritis; may be used with or without nonbiologic DMARDs IV infusion <60 kg: 500 mg 60-100 kg: 750 mg >100 kg: 1000 mg Maintenance: Above dose repeated q2Weeks X2, then q4Weeks SC injection 125 mg SC qWeek without the need for an IV loading dose Switching from IV to SC: Administer the first SC dose instead of the next scheduled IV dose Graft versus Host Disease Indicated for the prophylaxis of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor and methotrexate, in adults undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor Day -1 (day before transplantation): 10 mg/kg IV (up to 1,000 mg) IV, followed by Days 5, 14, and 28 (after transplantation): 10 mg/kg IV (up to 1,000 mg) IV Diabetes Mellitus Type 1 (Orphan) Orphan designation for treatment of type 1 diabetes mellitus in patients with residual beta cell function Orphan sponsor Orban Biotech LLC; 64 Aspinwall Avenue; Brookline, MA 02446-6495 Giant Cell Arteritis (Orphan) Orphan designation for giant cell arteritis Sponsor Bristol-Myers Squibb; P.O. Box 5326; Princeton, New Jersey 08543 Dosing Considerations Before initiating Update vaccinations in accordance with current vaccination guidelines Screen for viral hepatitis in accordance with published guidelines Tuberculosis (TB) Screen for TB infection with a tuberculin skin test Not studied in patients with a positive TB screen, and safety in individuals with latent TB infection is unknown Patients testing positive in TB screening should be treated by standard medical practice before therapy Limitations of use Use with other potent immunosuppressants (eg, biologic disease modifying antirheumatic drugs [bDMARDS], Janus kinas [JAK] inhibitors) Dosage Forms & Strengths injection, lyophilized powder for reconstitution 250mg/vial solution for SC injection 125mg/mL prefilled syringe Note: autoinjector has not been studied in patients aged <18 yr Juvenile Idiopathic Arthritis Indicated for reducing signs and symptoms in patients aged ≥2 years with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA); may be used as monotherapy or concomitantly with methotrexate SC administration <2 years: Safety and efficacy not established ≥2 years 10 to <25 kg: 50 mg SC once weekly 25 to <50 kg: 87.5 mg SC once weekly ≥50 kg: 125 mg SC once weekly Administer without a loading dose IV administration <6 years: Safety and efficacy not established ≥6 years old and <75 kg: Loading dose of 10 mg/kg IV over 30 minutes Maintenance: Same dose repeated 2 and 4 weeks after loading dose, THEN q4Weeks ≥75 kg: Administer as in adult Graft versus Host Disease Indicated for the prophylaxis of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients aged ≥2 years undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor <2 years: Safety and efficacy not established 2 to <6 years Day -1 (day before transplantation): 15 mg/kg IV, followed by Days 5, 14, and 28 (after transplantation): 12 mg/kg IV ≥6 years Day -1 (day before transplantation): 10 mg/kg IV (up to 1,000 mg) IV, followed by Days 5, 14, and 28 (after transplantation): 10 mg/kg IV (up to 1,000 mg) IV Dosing Considerations Before initiating Update vaccinations in accordance with current vaccination guidelines Screen for viral hepatitis in accordance with published guidelines Tuberculosis (TB) Screen for TB infection with a tuberculin skin test Not studied in patients with a positive TB screen, and safety in individuals with latent TB infection is unknown Patients testing positive in TB screening should be treated by standard medical practice before therapy Limitations of use Use with other potent immunosuppressants (eg, biologic disease modifying antirheumatic drugs [bDMARDS], Janus kinas [JAK] inhibitors) Interaction CheckerEnter a drug name and abataceptNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)upadacitinibabatacept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.Serious - Use Alternative (17)adalimumababatacept, adalimumab. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.adenovirus types 4 and 7 live, oralabatacept decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.anakinraabatacept, anakinra. Mechanism: unspecified interaction mechanism. Contraindicated. Concomitant use not recommended (in mfr. info.).axicabtagene ciloleucelabatacept, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibbaricitinib, abatacept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.brexucabtagene autoleucelabatacept, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.certolizumab pegolabatacept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.ciltacabtagene autoleucelabatacept, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.etanerceptabatacept, etanercept. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.idecabtagene vicleucelabatacept, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.infliximababatacept, infliximab. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.influenza virus vaccine quadrivalent, adjuvantedabatacept decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.influenza virus vaccine trivalent, adjuvantedabatacept decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.lisocabtagene maraleucelabatacept, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.tisagenlecleucelabatacept, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.tocilizumababatacept, tocilizumab. Mechanism: unspecified interaction mechanism. Contraindicated. Concomitant use not recommended (in mfr. info.).tofacitinibabatacept, tofacitinib. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.Monitor Closely (19)belataceptbelatacept and abatacept both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.cholera vaccineabatacept decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.dengue vaccineabatacept decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.denosumababatacept, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.fingolimodabatacept increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .hydroxyureahydroxyurea, abatacept. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of immunosuppression.isavuconazonium sulfateabatacept and isavuconazonium sulfate both decrease immunosuppressive effects; risk of infection. Use Caution/Monitor.meningococcal group B vaccineabatacept decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.ocrelizumababatacept and ocrelizumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with immunosuppessants is expected to increase the risk of immunosuppression.ofatumumab SCofatumumab SC, abatacept. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.olaparibabatacept and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity. ozanimodozanimod, abatacept. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects.ponesimodponesimod and abatacept both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.rozanolixizumababatacept will decrease the level or effect of rozanolixizumab by plasma protein binding competition. Use Caution/Monitor. Rozanolixizumab may lower systemic exposures and reduce effectiveness of medications that bind to the human neonatal Fc receptor (FcRn). Closely monitor for decreased efficacy of such medications. When long-term use of such medications is required, consider discontinuing rozanolixizumab and using alternative therapies.siponimodsiponimod and abatacept both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.sipuleucel-Tabatacept decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.trastuzumabtrastuzumab, abatacept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .trastuzumab deruxtecantrastuzumab deruxtecan, abatacept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .ublituximabublituximab and abatacept both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministeredMinor (0)adalimumabSerious - Use Alternative (1)abatacept, adalimumab. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.adenovirus types 4 and 7 live, oralSerious - Use Alternative (1)abatacept decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.anakinraSerious - Use Alternative (1)abatacept, anakinra. Mechanism: unspecified interaction mechanism. Contraindicated. Concomitant use not recommended (in mfr. info.).axicabtagene ciloleucelSerious - Use Alternative (1)abatacept, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibSerious - Use Alternative (1)baricitinib, abatacept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.belataceptMonitor Closely (1)belatacept and abatacept both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.brexucabtagene autoleucelSerious - Use Alternative (1)abatacept, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.certolizumab pegolSerious - Use Alternative (1)abatacept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.cholera vaccineMonitor Closely (1)abatacept decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.ciltacabtagene autoleucelSerious - Use Alternative (1)abatacept, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.dengue vaccineMonitor Closely (1)abatacept decreases effects